Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction.
about
History of clinical transplantationTransplantation tolerance and its outcome during infections and inflammationEffects of FK506 and cyclosporin A on cytokine production studied in vitro at a single-cell levelInduction of liver, heart, and multivisceral graft acceptance with a short course of FK 506Pathologic observations in human allograft recipients treated with FK 506Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications.Bioassay of plasma specimens from liver transplant patients on FK 506 immunosuppression.Liver transplantation: an unfinished productAdverse effects associated with the use of FK 506Current status of FK 506 in liver transplantation.FK506 suppression of heart and liver allograft rejection. II: The induction of graft acceptance in ratsFK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats.Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients.Effect of the immunosuppressant FK506 on glucose-induced insulin secretion from adult rat islets of LangerhansFK 506 for liver, kidney, and pancreas transplantation.Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506.Rapamycin but not FK506 inhibits the proliferation of mononuclear phagocytes induced by colony-stimulating factorsSpecies differences in sensitivity of T lymphocytes to immunosuppressive effects of FK 506.Prolongation of canine renal allograft survival by combining tacrolimus with antimetabolic agentsNotes on FK 506Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy.Kidney transplantation under FK 506Canine total orthotopic small bowel transplantation under FK 506.Microvascular changes in renal allografts associated with FK506 (Tacrolimus) therapyHepatic transplantation at the University of Pittsburgh: new horizons and paradigms after 30 years of experience.A prospective trial of tacrolimus (FK 506) in clinical heart transplantation: intermediate-term resultsInduction of graft acceptance after dog kidney or liver transplantationAdult heart transplantation under tacrolimus (FK506) immunosuppression: histopathologic observations and comparison to a cyclosporine-based regimen with lympholytic (ATG) inductionRenal dysfunction associated with liver transplantation.Primate models in organ transplantationEffects of cyclosporin A and FK506 on Fc epsilon receptor type I-initiated increases in cytokine mRNA in mouse bone marrow-derived progenitor mast cells: resistance to FK506 is associated with a deficiency in FK506-binding protein FKBP12.The immunosuppressant FK-506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1The present state of liver transplantation and the future prospects for intestinal transplantation.FK506 (tacrolimus), a novel immunosuppressant in organ transplantation: clinical, biomedical, and analytical aspects.Tacrolimus (FK506)-Associated Renal Pathology.Overview of FK506 in transplantationGastrointestinal and metabolic problems associated with immunosuppression with either CyA or FK 506 in liver transplantation.FK506 augments activation-induced programmed cell death of T lymphocytes in vivo.
P2860
Q24596303-20B25C42-B46E-4360-BCEE-4EC5FD3F6D94Q26829817-F290EC8B-E28E-464E-A3B2-FABAB8F46A22Q28316111-C196B398-975E-498D-A504-8ED8118B148BQ33993421-4097B8DA-CBF9-4E33-BF06-D5513F08A5E6Q33993438-D1EE41EF-915B-479E-9B8E-266B161D4BFDQ33993513-E2519A45-5D10-4297-8FEE-29EBE02E2D94Q33993525-1193A18A-AF77-4C7C-A0CA-D51661DCA929Q34177197-4CD95CF3-4160-4982-BD10-139FC313553FQ34187736-BC96943C-A7DB-4A77-BDBA-C54074788BC5Q34204368-531590A8-9C49-48F4-A15B-5C44B29C6BB6Q34207804-718A198D-6A40-4A7A-9A20-C94C7069015DQ34207851-EE4A2EA9-83CB-4594-A2CD-8D312035614AQ34232377-CF476CA7-772D-49C3-AA8B-C055BF139307Q34239900-43C0C2AD-7DE4-4B9E-B60D-1889F69990ECQ34252199-26893D8E-99A0-4CBF-9676-01A7A96F62FEQ34257382-F8124C91-AA85-4B5C-BA30-FFC5A1E883E1Q34275901-CF0DF778-CE81-4541-B518-AE4AA9C05C24Q34280890-A4EE5273-CDD9-4A04-8A41-AF0A65908C61Q34288885-DF1F7886-26C5-4447-B07C-950700179B4EQ34291577-41114654-8980-460E-8C30-86F60CDA9AC0Q34298815-0D78042B-F0EC-4C81-87AF-0175458701E6Q34302082-5A6BE56D-A86A-4968-AA43-F3311AC90875Q34481342-7650C600-DFD0-4000-A740-C262A7EB31C5Q34481437-F7577826-A766-4AFC-B6BA-34AD2DBBEB7DQ34498238-3C59FFA4-16AE-4182-A4D6-4E2BB87CB353Q34498286-837B3813-72A7-43ED-9F96-68E2B3A949F9Q34546642-FF391881-02A9-4274-98D1-FCD5E14A2667Q35253580-9214F3B8-8F60-4C0B-9193-AB409DD1E65BQ36680260-90F287C2-4264-4A68-8D7F-B861B1696672Q37122367-91FE95BE-FE85-4CD6-B73F-80A7ACC5E5C2Q37199196-17A491D4-BB71-4A31-81D5-BE0FD5D0EE3DQ38334131-B7ADD789-09D5-4384-BCFE-37F0ED4EB711Q38643487-B5CA8DDD-A3E4-4697-A586-86437AFFA69CQ40491507-65E9A866-4765-44B6-9A46-B2017EEAD284Q42010174-3605E925-2505-4BCC-A991-A48A48D68587Q42719296-D3BB7E2B-8FAE-48C6-B30D-5737EB2E18F1Q42733440-6CD80297-3983-4745-9F6B-375D066C1797Q42929438-F4754A8F-E796-4826-B1B9-20526F739D1C
P2860
Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction.
description
1988 nî lūn-bûn
@nan
1988 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1988 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
name
Immunosuppression of canine, m ...... gs and to tolerance induction.
@ast
Immunosuppression of canine, m ...... gs and to tolerance induction.
@en
Immunosuppression of canine, m ...... gs and to tolerance induction.
@nl
type
label
Immunosuppression of canine, m ...... gs and to tolerance induction.
@ast
Immunosuppression of canine, m ...... gs and to tolerance induction.
@en
Immunosuppression of canine, m ...... gs and to tolerance induction.
@nl
prefLabel
Immunosuppression of canine, m ...... gs and to tolerance induction.
@ast
Immunosuppression of canine, m ...... gs and to tolerance induction.
@en
Immunosuppression of canine, m ...... gs and to tolerance induction.
@nl
P2093
P2860
P1433
P1476
Immunosuppression of canine, m ...... ugs and to tolerance induction
@en
P2093
J A Demetris
M Nalesnik
O Imventarza
R Venkataramanan
P2860
P304
P407
P577
1988-08-01T00:00:00Z